• Federal Court Holds that Mevacor (Lovastatin) Patent is Valid and Infringed
  • January 14, 2011
  • Law Firm: Norton Rose OR LLP - Montreal Office
  • The ‘380 Patent describes and claims the medicine lovastatin when made by a process involving a microorganism knownas Aspergillus terreus (also known as A. terreus). Lovastatin was first approved for sale by Merck Frosst Canada Ltd. under the brand name MEVACOR and is used for the treatment of elevated blood cholesterol. The application for the ‘380 Patent was filed in Canada on June 11, 1980 and issued on January 31, 1984 to Merck & Co. Inc. The ‘380 Patent is governed by the Patent Act as it read prior to October 1, 1989.